Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction

FMC

04/02/2026 22:11

Overview

Agricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yr

Adjusted EPS for Q4 fell 33% yr/yr due to lower EBITDA and goodwill impairment

Company to explore strategic options, including potential sale, to enhance shareholder value

Outlook

FMC expects 2026 revenue between $3.60 bln and $3.80 bln, a 5% decline at midpoint

Adjusted EBITDA for 2026 projected at $670 mln to $730 mln, down 17%

FMC forecasts 2026 adjusted EPS between $1.63 and $1.89, a 41% decrease

Result Drivers

PRICE DECLINES - Revenue decline driven by 6% price reduction, primarily in Rynaxypyr, amid competitive pressures

NEW INGREDIENTS - Growth in new active ingredients like Isoflex and fluindapyr, despite overall revenue decline

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$1.08 bln
$1.15 bln (14 Analysts)

Press Release: ID:nPn4p3X6ra

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)